Chenguang Biotech announced that the company recently received a decision on administrative supervision measures issued by the Xinjiang Securities Regulatory Bureau. Since the company received a total of 136 million yuan of loan capital from March to April 2025 from the subsidiary Shengyuan Biotech's wholly-owned subsidiary within the scope of the consolidated statement, constituting non-operating capital occupation, it was taken to supervise and manage measures ordering corrections and issuing warning letters, and included in the securities and futures market integrity file.

Chenguang Biotech announced that the company recently received a decision on administrative supervision measures issued by the Xinjiang Securities Regulatory Bureau. Since the company received a total of 136 million yuan of loan capital from March to April 2025 from the subsidiary Shengyuan Biotech's wholly-owned subsidiary within the scope of the consolidated statement, constituting non-operating capital occupation, it was taken to supervise and manage measures ordering corrections and issuing warning letters, and included in the securities and futures market integrity file.